Clear All
716 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
J9041 Bortezomib Velcade 0.1 mg Chemotherapy Proteasome Inhibitor 26S No 2003 Jan 1, 2005 In Use
J9046 Bortezomib (Dr Reddy) Bortezomib (Dr Reddy) 0.1mg Chemotherapy Proteasome Inhibitor 26S No 2022 Dec 21, 2022 In Use
J9048 Bortezomib (Fresniuskab) Bortezomib (Fresniuskab) 0.1mg Chemotherapy Proteasome Inhibitor 26S No 2017 Dec 21, 2022 In Use
J9049 Bortezomib (Hospira) Bortezomib (Hospira) 0.1mg Chemotherapy Proteasome Inhibitor 26S No 2022 Dec 21, 2022 In Use
J9051 Bortezomib (Maia) Bortezomib 0.1mg Chemotherapy Proteasome Inhibitor 26S Yes 2022 Aug 28, 2023 In Use
NA Brigatinib Alunbrig 30 mg Chemotherapy Tyrosine Kinase Inhibitor ALK Yes 2017 In Use
NA Bromocriptine Mesylate Parlodel Chemotherapy Dopamine Agonist Ergot Derivative Yes 1978 In Use
J8510 Busulfan Myleran 2 mg Chemotherapy Alkylating Agent Alkylsulfonate Yes 1954 Jan 1, 2000 In Use
J9064 Cabazitaxel (Sandoz) Cabazitaxel 1mg Chemotherapy Antimitotic Agent Taxane No 2023 Aug 28, 2023 In Use
NA Cabozantinib Cabometyx 60 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2012 In Use
NA Cabozantinib Cabometyx 20 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2012 In Use
NA Cabozantinib Cabometyx 40 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2012 In Use
NA Cabozantinib Cometriq 20 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2012 In Use
NA Bosutinib Bosulif 100 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2012 In Use
NA Bosutinib Bosulif 500 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2012 In Use
J9042 Brentuximab vedotin Adcetris 1 mg Immunotherapy Drug Antibody Conjugate CD30 No 2011 Jan 1, 2013 In Use
Q2053 Brexucabtagene autoleucel Tecartus 2000000 Immunotherapy CAR-T CD-19 No 2020 Apr 1, 2021 In Use
Q5129 Bevacizumab-adcd Vegzelma 10mg Immunotherapy Monoclonal Antibody VEGFR No 2023 Mar 17, 2023 In Use
J8530 Cyclophosphamide Cyclophosphamide oral 25 mg Chemotherapy Alkylating Agent Nitrogen Mustard Yes 1959 Jan 1, 1995 In Use
J9071 Cyclophosphamide (AuroMedics) Cyclophosphamide 5mg Chemotherapy Alkylating Agent Nitrogen mustard No 2021 Mar 25, 2022 In Use
J9072 Cyclophosphamide (Dr Reddy's) Cyclophosphamide 5mg Chemotherapy Alkylating Agent Nitrogen Mustard No 2023 Dec 7, 2023 In Use
J0894 Decitabine Dacogen 1 mg Chemotherapy Antimetabolite Pyrimidine Analog No 2006 Jan 1, 2007 In Use
J0893 Decitabine (Sun Pharma) Decitabine 1mg Chemotherapy Antimetabolite Pyrimidine Analog No 2014 Dec 21, 2022 In Use
J9179 Eribulin mesylate Halaven 0.1 mg Chemotherapy Antimitotic Agent Furopyrans No 2010 Jan 1, 2012 In Use
J9150 Daunorubicin Daunorubicin Hydrochloride 10 mg Chemotherapy Antitumor Antibiotic Anthracycline No 1996 Jan 1, 1986 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.